Upcoming AWS Coverage on Akorn Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 13, 2017 / Active Wall St. blog coverage looks at the headline from Mylan N.V. (NASDAQ: MYL) as the Company announced on March 10, 2017, the launch of the generic version of Pfizer Inc.'s (NYSE: PFE) Antidepressant PRISTIQ (Desvenlafaxine) in the US. Mylan's generic Desvenlafaxine will be available as extended-release tablets of 50mg and 100mg doses across the US drug stores and pharmacies. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Mylan's competitors within the Drugs - Generic space, Akorn, Inc. (NASDAQ: AKRX), reported on March 01, 2017, its financial results for Q4 2016 and full year 2016, and provided full year 2017 guidance. AWS will be initiating a research report on Akorn in the coming days.

Today, AWS is promoting its blog coverage on MYL; touching on AKRX. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Mylan's launch was announced following the US Food and Drug Administration (FDA)'s final approval for the Abbreviated New Drug Application (ANDA) for Desvenlafaxine, which would be used in the treatment of major depressive disorder.

As per the data available with IMS Health, (a global Company that provides information, services, and technology for the healthcare industry), at present Mylan has a line-up of 241 ANDAs which are awaiting FDA approval and which represent a potential annual brand sales of $100.9 billion. Out of these 241 ANDAs, 45 ANDAs are potential first-to-file opportunities and represent $39 billion in annual brand sales for the 12-month period ending on December 31, 2016.

About Pfizer's PRISTIQ

Pfizer's PRISTIQ® (Desvenlafaxine) is FDA an approved antidepressant drug, and the drug was launched in 2008. Desvenlafaxine is a prescription medication used for the treatment of major depressive disorder in adults. PRISTIQ is in a class of medications known as SNRIs, or serotonin-norepinephrine reuptake inhibitors. Serotonin and norepinephrine are chemicals that relay messages from one brain cell to another. PRISTIQ is thought to work by affecting the levels of these two brain chemicals, both thought to play a role in depression.

According to IMS Health, the US sales for extended-release tablets of Pfizer's PRISTIQ (Desvenlafaxine)'s 50mg and 100mg doses was $853 million for the 12-month period ending on January 31, 2017. However, these antidepressants are not approved for children, adolescents, and young adults as they can increase the risk of suicidal thinking.

Generics of PRISTIQ

Mylan's launch of the generic version of PRISTIQ was shadowed by the earlier launch of the generic version of the same drug by two other Pharmaceutical Companies for the US markets. The generic version of PRISTIQ was earlier launched by Israeli generics giant Teva Pharmaceutical Industries and Indian Pharmaceutical major Lupin in the US on March 01, 2017. Both Companies have received USFDA approvals for their generic versions. Teva's generic PRISTIQ® (Desvenlafaxine) was launched in extended-release tablets form in doses of 25 mg, 50 mg, and 100 mg. Lupin's version of generic PRISTIQ® (Desvenlafaxine Succinate) was also launched in extended-release tablets form in doses of 50 mg and 100 mg.

Recent Earnings Highlights

Mylan is a global generic and speciality pharmaceutical Company that is known for its signature product EpiPen®. Recently, Mylan had announced its financial performance for the FY16 on March 01, 2017. The Company's total revenues for the FY16 were $11.08 billion with a GAAP EPS of $0.92 and an adjusted EPS of $4.89. The Company also provided financial guidance for FY17 and expects its revenues to be in the range of $12.25 billion - $13.75 billion and adjusted EPS to be in the range of $5.15 - $5.55 per share.

Stock Performance

On Friday, March 10, 2017, the stock closed the trading session at $43.40, marginally rising 0.39% from its previous closing price of $43.23. A total volume of 3.67 million shares have exchanged hands. Mylan's stock price advanced 10.74% in the last month, 25.80% in the past three months, and 6.98% in the previous six months. Furthermore, on a year to date basis, the stock surged 13.76%. Shares of the company have a PE ratio of 47.85 and have a market capital of $23.15 billion.

Pfizer's stock closed last Friday's trading session with a slight gain of 0.18% at $34.11. Approximately 18.95 million of the Company's shares exchanged hands by the end of the day. The stock performance in the last month and the last quarter was in the green as the stock advanced 6.13% and 10.48%, respectively. The six-month performance was 0.23% as compared to the yearly performance of 19.65%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street